Current perspectives on the treatment of primary chronic ITP in adults
Current perspectives on the treatment of primary chronic ITP in adults
Dr. David J. Kuter, Prof. Pål Andrè Holme, Dr. Vickie McDonald, Prof. Jerzy Windyga
Understand how treatment for primary chronic immune thrombocytopenia (ITP) in adults has evolved, hear current perspectives on the treatment of ITP in the COVID-19 era and look into the future with world-class expertsDr. David J. Kuter
Haematologist
Massachusetts General Hospital and Harvard Medical School
United States (US)
Prof. Pål Andrè Holme
Haematologist
Oslo University Hospital
Norway
Dr. Vickie McDonald
Haematologist
Royal London Hospital and Queen Mary University of London
United Kingdom (UK)
Prof. Jerzy Windyga
Haematologist
Institute of Hematology and Transfusion Medicine
Poland
Dr. David J. Kuter
Haematologist
Massachusetts General Hospital and Harvard Medical School
United States (US)
Dr. David J. Kuter has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Pål Andrè Holme
Haematologist
Oslo University Hospital
Norway
Prof. Pål Andrè Holme has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Dr. Vickie McDonald
Haematologist
Royal London Hospital and Queen Mary University of London
United Kingdom (UK)
Dr. Vickie McDonald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Jerzy Windyga
Haematologist
Institute of Hematology and Transfusion Medicine
Poland
Prof. Jerzy Windyga has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Webinar | 60 min |accreditation: EBAC | Jul 2020
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This CME-accredited symposium took place during the ISTH virtual congress on 14th July 2020.
The broader educational objectives of this programme are:
- Review of the current standard of care in ITP, detailing its risk and benefit
- Explain the mechanism of action and clinical data of potential new and innovative therapeutic options in ITP
- Comparison of standard of care today and in the future
The live event 'Current Perspectives on the Treatment of Primary Chronic ITP in Adults' took place during ISTH 2020 on 14th July 2020 and has been accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. Please note: CME credit can only be claimed for attending the live event on 14th July 2020.
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credit™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website https://edhub.ama-assn.org/pages/applications. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.